RIGL Q3 2024 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+96.6% YoY

Gross Profit

$47M85.5% margin

Operating Income

$14M25.4% margin

Net Income

$12M22.5% margin

EPS (Diluted)

$0.70

QoQ Revenue Growth

+50.1%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$139M

Total Liabilities

$154M

Stockholders' Equity

-$15M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$28M	+96.6%
Gross Profit	$47M	$27M	+76.0%
Operating Income	$14M	-$4M	+414.8%
Net Income	$12M	-$6M	+318.2%

Revenue Segments

Gross product sales

$56M54%

Product sales, net

$39M37%

Revenues from collaborations

$16M16%

License

$10M10%

Discounts and allowances

-$17M-17%